S&P 500   3,390.68 (+0.60%)
DOW   29,378.32 (+0.50%)
QQQ   237.07 (+1.00%)
AAPL   324.34 (+1.67%)
FB   217.03 (-0.35%)
MSFT   187.25 (+0.01%)
GOOGL   1,526.66 (+0.47%)
AMZN   2,182.43 (+1.24%)
CGC   21.79 (-0.68%)
NVDA   311.15 (+4.92%)
BABA   222.00 (+0.67%)
MU   58.83 (+1.87%)
GE   12.92 (+1.33%)
TSLA   937.00 (+9.16%)
AMD   58.59 (+2.99%)
ACB   1.71 (+4.27%)
F   8.05 (-0.25%)
BAC   34.71 (+1.28%)
DIS   140.60 (+1.05%)
GILD   66.99 (-0.03%)
S&P 500   3,390.68 (+0.60%)
DOW   29,378.32 (+0.50%)
QQQ   237.07 (+1.00%)
AAPL   324.34 (+1.67%)
FB   217.03 (-0.35%)
MSFT   187.25 (+0.01%)
GOOGL   1,526.66 (+0.47%)
AMZN   2,182.43 (+1.24%)
CGC   21.79 (-0.68%)
NVDA   311.15 (+4.92%)
BABA   222.00 (+0.67%)
MU   58.83 (+1.87%)
GE   12.92 (+1.33%)
TSLA   937.00 (+9.16%)
AMD   58.59 (+2.99%)
ACB   1.71 (+4.27%)
F   8.05 (-0.25%)
BAC   34.71 (+1.28%)
DIS   140.60 (+1.05%)
GILD   66.99 (-0.03%)
S&P 500   3,390.68 (+0.60%)
DOW   29,378.32 (+0.50%)
QQQ   237.07 (+1.00%)
AAPL   324.34 (+1.67%)
FB   217.03 (-0.35%)
MSFT   187.25 (+0.01%)
GOOGL   1,526.66 (+0.47%)
AMZN   2,182.43 (+1.24%)
CGC   21.79 (-0.68%)
NVDA   311.15 (+4.92%)
BABA   222.00 (+0.67%)
MU   58.83 (+1.87%)
GE   12.92 (+1.33%)
TSLA   937.00 (+9.16%)
AMD   58.59 (+2.99%)
ACB   1.71 (+4.27%)
F   8.05 (-0.25%)
BAC   34.71 (+1.28%)
DIS   140.60 (+1.05%)
GILD   66.99 (-0.03%)
S&P 500   3,390.68 (+0.60%)
DOW   29,378.32 (+0.50%)
QQQ   237.07 (+1.00%)
AAPL   324.34 (+1.67%)
FB   217.03 (-0.35%)
MSFT   187.25 (+0.01%)
GOOGL   1,526.66 (+0.47%)
AMZN   2,182.43 (+1.24%)
CGC   21.79 (-0.68%)
NVDA   311.15 (+4.92%)
BABA   222.00 (+0.67%)
MU   58.83 (+1.87%)
GE   12.92 (+1.33%)
TSLA   937.00 (+9.16%)
AMD   58.59 (+2.99%)
ACB   1.71 (+4.27%)
F   8.05 (-0.25%)
BAC   34.71 (+1.28%)
DIS   140.60 (+1.05%)
GILD   66.99 (-0.03%)
Log in

ASX:SUD - Suda Pharmaceuticals Stock Price, Forecast & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume3.96 million shs
Average VolumeN/A
Market Capitalization$15.49 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Suda Pharmaceuticals Ltd operates as a drug delivery company that focuses on oro-mucosal administration in Australia. Its product pipeline includes ZolpiMist, a US approved, oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia; ArTiMist, a sub-lingual spray for the treatment of p. falciparum severe paediatric malaria; SUD-001, an oral spray formulation that is used for the treatment of acute migraine in adults; and SUD-002, an oral spray formulation of ondansetron to treat nausea and vomiting induced by chemotherapy or radiotherapy, and other post-operative settings. Its product pipeline also comprises SUD-003, an oral spray formulation of sildenafil sprayed directly in the mouth over the tongue for the treatment of erectile dysfunction; SUD-004, an oral spray formulation of sildenafil to treat pulmonary arterial hypertension in adults; and SUD-005, an oral spray formulation of midazolam for the treatment of pre-procedure anxiety in imaging and dental procedures, and also in the treatment of epileptic seizures. In addition, it distributes medical devices, pharmaceuticals, vaccines, and consumables to hospitals, aged care facilities, pharmacies, mining companies, and other healthcare providers. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH for ZolpiMist oral spray. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd is based in Osborne Park, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 8 6142 5555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.25 million
Book ValueA$0.10 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$15.49 million
Next Earnings DateN/A
OptionableNot Optionable

Receive SUD News and Ratings via Email

Sign-up to receive the latest news and ratings for SUD and its competitors with MarketBeat's FREE daily newsletter.


Suda Pharmaceuticals (ASX:SUD) Frequently Asked Questions

What is Suda Pharmaceuticals' stock symbol?

Suda Pharmaceuticals trades on the ASX under the ticker symbol "SUD."

Has Suda Pharmaceuticals been receiving favorable news coverage?

News stories about SUD stock have been trending somewhat negative on Wednesday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Suda Pharmaceuticals earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Suda Pharmaceuticals.

Who are some of Suda Pharmaceuticals' key competitors?

Who are Suda Pharmaceuticals' key executives?

Suda Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen Carter, CEO & MD
  • Mr. Joseph Daniel Ohayon, CFO & Company Sec.
  • Dr. Carol Worth, Chief Technical Officer

How big of a company is Suda Pharmaceuticals?

Suda Pharmaceuticals has a market capitalization of $0.00 and generates $1.25 million in revenue each year. View Additional Information About Suda Pharmaceuticals.

What is Suda Pharmaceuticals' official website?

The official website for Suda Pharmaceuticals is http://sudapharma.com/.

How can I contact Suda Pharmaceuticals?

The company can be reached via phone at 61 8 6142 5555.


MarketBeat Community Rating for Suda Pharmaceuticals (ASX SUD)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  9 (Vote Outperform)
Underperform Votes:  8 (Vote Underperform)
Total Votes:  17
MarketBeat's community ratings are surveys of what our community members think about Suda Pharmaceuticals and other stocks. Vote "Outperform" if you believe SUD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: Coverage Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel